[Production of the therapeutic and prophylactic preparation enterobifidin on the basis of Bifidobacterium adolescentis MC-42].
Production of Enterobifidin comprises preparation of culture media, reparation of lyophilized Bifidobacterium adolescentis MS-42 culture, preparation of starters, cultivation of bacteria in fermenters, biomass conservation, and its biological control. The preparation contains physiologically active bifidobacterium cells with high activities of growth (mu = 0.7 h-1, g = 1.0 h) and acid formation (titratable acidity is approximately 120-140 degrees T; acetate concentration, 0.50-0.75%; and lactate concentration, 0.33-0.50%). The antagonistic activity of these bacteria towards Escherichia coli 08, E. coli 086, E. coli 015, E. coli 0115, and E. coli 0101 amounts to 98.2;, to Proteus vulgaris 102, to 87.2; and Staphylococcus aureus 209p, to 83.2%. The bifidobacteria (with a titer of 10(9) CFU/ml) remained viable for two to five months.
Novik
G I
GI
Institute of Microbiology, National Academy of Sciences of Belarus, Minsk, Belarus.
Astapovich
N I
NI
Bogdanovskaia
Zh N
ZhN
Riabaia
N E
NE
D000900:Anti-Bacterial Agents / Q000378:metabolism*; D001644:Bifidobacterium / Q000254:growth & development / Q000378:metabolism*; D001688:Biological Products / Q000096:biosynthesis*; D007700:Kinetics
D000900:Anti-Bacterial Agents; D001688:Biological Products; C010546:bifidobacterin